Literature DB >> 6165243

Renal involvement in Refsum's disease.

R C Pabico, B J Gruebel, B A McKenna, R C Griggs, J Hollander, J Nusbacher, B J Panner.   

Abstract

Renal hemodynamic and tubular functions were measured in a patient with Refsum's disease before and after 12 weeks of twice-weekly plasmaphereses. Percutaneous renal biopsy was performed before initiation of plasmapheresis. These studies were performed to (1) define the nature of the renal lesions and the effects of phytanic acid accumulation on renal functions, and (2) assess the effects of lowering the plasma phytanic acid level on renal functions. The patient, a 39 year old woman, had lipiduria, glycosuria, cylindruria, minimal proteinuria and mild azotemia initially. Renal lesions consist of extensive vacuolization and mitochondrial changes of the tubular epithelial cells, vacuolization of the visceral epithelial cells of the glomeruli, and slight to moderate mesangial sclerosis. The impaired renal hemodynamic function and various tubular functions improved following plasmaphereses associated with reduction of plasma phytanic acid. Over-all clinical improvement was also evident.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165243     DOI: 10.1016/0002-9343(81)90889-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  Refsum's disease: long term treatment preserves sensory nerve action potentials and motor function.

Authors:  J S Lou; R Snyder; R C Griggs
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

2.  Plasma exchange in the treatment of Refsum's disease (heredopathia atactica polyneuritiformis).

Authors:  D Harari; F B Gibberd; J P Dick; M C Sidey
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-07       Impact factor: 10.154

3.  Hypokalaemia in acute Refsum's disease.

Authors:  J P Dick; K Meeran; F B Gibberd; F C Rose
Journal:  J R Soc Med       Date:  1993-03       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.